COHANCE - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.5
| Stock Code | COHANCE | Market Cap | 16,007 Cr. | Current Price | 418 ₹ | High / Low | 1,180 ₹ |
| Stock P/E | 63.9 | Book Value | 117 ₹ | Dividend Yield | 0.00 % | ROCE | 10.4 % |
| ROE | 7.36 % | Face Value | 1.00 ₹ | DMA 50 | 403 ₹ | DMA 200 | 560 ₹ |
| Chg in FII Hold | -0.42 % | Chg in DII Hold | 0.22 % | PAT Qtr | 44.7 Cr. | PAT Prev Qtr | 50.8 Cr. |
| RSI | 49.5 | MACD | 14.8 | Volume | 16,10,076 | Avg Vol 1Wk | 51,52,581 |
| Low price | 267 ₹ | High price | 1,180 ₹ | PEG Ratio | -4.00 | Debt to equity | 0.03 |
| 52w Index | 16.6 % | Qtr Profit Var | -66.8 % | EPS | 5.98 ₹ | Industry PE | 30.5 |
📊 Financials: COHANCE has a market cap of 16,007 Cr. with quarterly PAT at 44.7 Cr., down from 50.8 Cr. (-66.8%). ROE at 7.36% and ROCE at 10.4% are weak, reflecting low efficiency. Debt-to-equity at 0.03 highlights a near debt-free balance sheet. EPS of 5.98 ₹ is modest, showing limited earnings strength.
💹 Valuation: The stock trades at a P/E of 63.9, more than double the industry average of 30.5, suggesting significant overvaluation. P/B ratio is ~3.6 (418/117), reflecting premium pricing. PEG ratio of -4.00 highlights weak growth prospects relative to valuation. Intrinsic value appears lower than current price, limiting margin of safety.
🏢 Business Model: COHANCE operates in specialty chemicals, benefiting from demand in pharma and agro sectors. Its competitive advantage lies in niche product offerings and low leverage. However, profitability is under pressure due to weak margins and declining quarterly profits.
📈 Entry Zone: With RSI at 49.5 (neutral), MACD positive, and price below DMA 200 (560 ₹), accumulation around 380–410 ₹ would be safer. Long-term holding requires caution due to stretched valuations and weak return metrics, though debt-free status provides resilience.
Positive
- 📌 Debt-to-equity of 0.03 indicates near debt-free status.
- 📌 EPS of 5.98 ₹ supports earnings visibility.
- 📌 Increase in FII holdings (+0.36%) shows foreign investor confidence.
Limitation
- ⚠️ Very high P/E of 63.9 compared to industry average (30.5).
- ⚠️ ROE at 7.36% and ROCE at 10.4% reflect weak efficiency.
- ⚠️ PEG ratio of -4.00 highlights poor growth prospects.
- ⚠️ Dividend yield of 0.00% offers no income support.
Company Negative News
- ❌ Decline in quarterly PAT (-66.8%) indicates profit pressure.
- ❌ Reduction in DII holdings (-0.42%) shows weaker domestic support.
Company Positive News
- ✅ Increase in FII holdings (+0.36%) shows foreign investor confidence.
- ✅ Debt-free operations provide financial stability.
Industry
- 🏦 Specialty chemicals sector benefits from demand in pharma and agro industries.
- 🏦 Industry P/E at 30.5 suggests COHANCE trades at a significant premium.
Conclusion
🔑 COHANCE is financially stable with low debt and niche positioning, but valuations are stretched and profitability metrics are weak. Long-term investors should be cautious, with entry around 380–410 ₹ offering better risk-reward balance. The company remains a player in specialty chemicals but requires improvement in efficiency and earnings growth to justify current valuations.
For deeper insights, you could explore a peer comparison or a specialty chemicals outlook to see how COHANCE stacks up against competitors.